Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: August 28, 2019
Event: Filing of a new prospectus supplement regarding an at-the-market equity offering.
Key Financial Metrics
This filing does not report historical financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to the proposed capital raise:
- Aggregate Offering Price: Up to $1,950,000.
- Instrument: Common Stock, par value $0.001 per share.
- Sales Agent: H.C. Wainwright & Co., LLC.
Material Changes
The filing announces the initiation of a new offering under the Company's existing at-the-market equity offering program. This represents a potential increase in share count and capital, contingent upon the sale of shares. No material changes to prior period financial results are reported in this document.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use net proceeds, if any, for:
- Research and development related to product candidates.
- Manufacturing of products.
- Working capital and general corporate purposes.
- Potential acquisitions or other business combinations.
Management Commentary: The Company reserves the right to reallocate proceeds at the discretion of its Board of Directors. The Company states it cannot specify with certainty all particular uses for the net proceeds at this time.
Investor Verification Checklist
- Verify the actual number of shares sold and total net proceeds received, as the $1,950,000 figure represents the maximum aggregate offering price, not a guaranteed amount.
- Review the Common Stock Sales Agreement with H.C. Wainwright & Co., LLC for commission rates and sales terms.
- Check subsequent filings to confirm if the offering was fully utilized or terminated.
- Assess the dilution impact on existing shareholders based on the final number of shares issued.